资源描述：
《曲美布汀联合莫沙必利治疗功能性消化不良113例》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、医药导报2014年7月第33卷第7期·887··消化系统疾病用药专栏·*曲美布汀联合莫沙必利治疗功能性消化不良113例12111胡迎宾,冯觉平,彭娜,吕飞,郭秋霞(华中科技大学同济医学院附属普爱医院1.消化内科;2.肿瘤内科,武汉430033)摘要目的观察曲美布汀联合莫沙必利治疗功能性消化不良的疗效和安全性。方法将功能性消化不良患者347例,随机分为曲美布汀组(治疗A组)和莫沙必利组(治疗B组)各116例,曲美布汀联合莫沙必利组(联合组)115例。治疗A组给予马来酸曲美布汀片0.2g,tid,饭后服;治疗B组给予枸橼酸莫沙必利片5mg,tid,饭前服;联合组
2、给予马来酸曲美布汀片联合枸橼酸莫沙必利片,其中马来酸曲美布汀片每次0.2g,tid,饭后服,枸橼酸莫沙必利片每次5mg,tid,饭前服。3组患者疗程均为4周。评价各组症状改善指标和不良反应。结果347例入选患者中339例完成治疗和随访。联合组治疗4周后餐后饱胀不适、早饱感、上腹痛、上腹烧灼感、上腹胀和恶心症状总有效率分别为88.4%,76.9%,72.9%,61.8%,86.7%和81.7%,餐后饱胀不适、早饱感、上腹痛、上腹胀和恶心症状改善明显优于治疗A组和治疗B组(P<0.05)。3组上腹部烧灼感症状改善差异无统计学意义(P<0.05)。治疗A组、治疗B
3、组和联合组治疗4周后总体症状总有效率分别为60.2%,61.1%,78.8%,联合组显著优于其他两组(P<0.05)。治疗A组、治疗B组和联合组总不良反应发生率分别为1.8%,0.9%和1.8%(P=0.776),均较轻。结论曲美布汀联合莫沙必利可明显改善功能性消化不良患者的症状,且不良反应少。关键词曲美布汀;莫沙必利;消化不良,功能性中图分类号R57;R975文献标识码A文章编号1004-0781(2014)07-0887-04EfficacyofTrimebutineCombinedwithMosaprideonFunctionalDyspepsia12
4、111HUYing-bin,FENGJue-ping,PENGNa,LVFei,GUOQiu-xia(1.DepartmentofGastroenterology;2.DepartmentofOncology,thePu'aiHospitalAffiliatedtoTongjiMedicalCollege,HuazhongUniversityofScienceandTechnology,Wuhan430033,China)ABSTRACTObjectiveToevaluatetheefficacyandsafetyoftrimebutinecombinedw
5、ithmosaprideonfunctionaldyspepsia.MethodsPatientswithfunctionaldyspepsiawererandomlydividedintothreeclinicalgroups.GroupA(n=116)received0.2gtrimebutineaftermeal,groupthedrugcombinationB(n=116)received5mgmosapridebeforemeal,andthedrugcombinationgroup(n=115)received0.2gtrimebutineaft
6、ermealplus5mgmosapridebeforemeal.Allmedicationsweretakenorallythreetimesdailyfor4weeks.Improvementinclinicalsymptomsandadversereactionsineachgroupwereevaluatedattheendofstudy.ResultsAtotalof339patientsamong347enrolleescompletedthetreatmentandfollow-up.Theclinicalefficacyonpostprand
7、ialfullness,earlysatiation,epigastricpain,epigastricburning,upperabdominalbloatingandnauseawere88.4%,76.9%,72.9%,61.8%,86.7%and81.7%,respectivelyinthedrugcombinationgroupafter4-weektreatment,whichweresuperiortothoseingroupAorB(P<0.05)exceptforepigastricburning.Thetotaleffectiverate
8、ofthedrugcombinationgroupw
